Insmed (INSM) is a publicly traded Healthcare sector company. As of May 21, 2026, INSM trades at $107.56 with a market cap of $23.23B and a P/E ratio of -18.64. INSM moved +0.37% today. Year to date, INSM is -38.41%; over the trailing twelve months it is +57.51%. Its 52-week range spans $60.40 to $212.75. Analyst consensus is strong buy with an average price target of $203.20. Rallies surfaces INSM's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Insmed Target Cut to $185 Signals 58.7% Upside Despite 23% Q1 Revenue Miss: Insmed’s price target was lowered to $185, implying 58.7% upside from its $116.56 trading level despite shares plunging 23% after Q1 results. The company posted $305.96M in quarterly revenue (versus $308.1M expected) and improved its loss to $0.76 per share from an anticipated $0.90.
| Metric | Value |
|---|---|
| Price | $107.56 |
| Market Cap | $23.23B |
| P/E Ratio | -18.64 |
| EPS | $-5.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $212.75 |
| 52-Week Low | $60.40 |
| Volume | 2.61M |
| Avg Volume | 0 |
| Revenue (TTM) | $819.56M |
| Net Income | $-1.18B |
| Gross Margin | 81.81% |
16 analysts cover INSM: 0 strong buy, 16 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $203.20.